Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, June 28, 2016

Public edition |

Newswise Cancer Research Wire for 28-Jun-2016

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

Two-in-One Approach Could Help Keep Brain Cancer in Check

Two-in-one approach could help keep brain cancer in check

 • Image(s) embedded •  (Embargo expired on 28-Jun-2016 at 03:05 ET)

eLife, 28 June 2016

– MRC Clinical Sciences Centre/Institute of Clinical Sciences (ICS) Faculty of Medicine, Imperial College London

Relapse of Leukemia After Bone Marrow Transplantation: Cytomegalovirus Infection Has No Protective Effect

Recent studies on a small number of patients with leukemia treated with bone marrow transplantation have suggested that the presence of the common cytomegalovirus (CMV) in patients or their donors may protect against relapse or even death after the transplant. A large international study published in the journal Blood now shows the opposite. The virus not only does not prevent leukemia relapse, but also remains a major factor associated with the risk of death.

Blood, May 2016; U.S. National Institutes of Health and the U.S. Health Resources and Services Administration

– Universite de Montreal

Prostate Cancer Researchers Use Liquid Biopsy Biomarkers to Identify Aggressive Disease Before Treatment

Prostate cancer researchers have discovered biomarkers using non-invasive liquid biopsies to identify aggressive disease before surgery.

 • Video / Image(s) embedded • 

– University Health Network (UHN)

Researchers Discover Protein Signatures for Accurate Non-Invasive Diagnosis of Aggressive Prostate Cancer

Researchers at the Ontario Institute for Cancer Research (OICR) and University Health Network (UHN) in Toronto, along with researchers at the Eastern Virginia Medical School, have created protein signatures that accurately diagnose prostate cancer and can distinguish between patients with aggressive versus non-aggressive disease using a simple urine sample.

Nature Communications

– Ontario Institute for Cancer Research

3D Printed Kidney Helps Doctors Save Woman's Organ During Complicated Tumor Removal

Doctors and scientists at Intermountain Medical Center in Salt Lake City printed and used a 3D kidney to help save a patient's organ during a complicated tumor-removal procedural.

 • Image(s) embedded • 

– Intermountain Medical Center

International Lung Cancer Experts Seek Public Comments on Revised Molecular Testing Guideline to Improve Patient Selection and Targeted Therapies

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.”

– Association for Molecular Pathology

Researchers Develop Method to Map Cancer Progression

A team of scientists has developed a computational method to map cancer progression, an advance that offers new insights into the factors that spur this affliction as well as new ways of selecting effective therapies.

(Embargo expired on 27-Jun-2016 at 15:00 ET)

Proceedings of the National Academy of Sciences

– New York University

Researchers Find a Likely Cause of Inflammatory Myofibroblastic Tumors

Researchers at University of California San Diego School of Medicine have found that a likely cause of inflammatory myofibroblastic tumors is deficiency in nonsense-mediated RNA decay (NMD), a system cells use to control which genes are activated.

 • Image(s) embedded •  (Embargo expired on 27-Jun-2016 at 16:00 ET)

Journal of Clinical Investigation

– University of California San Diego Health Sciences

TSRI Scientists Find New Cancer Drug Target in Dual-Function Protein

Scientists at The Scripps Research Institute have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients. The new findings suggest that future therapies might target this protein, called GlyRS, to halt cancer growth.

 • Image(s) embedded •  (Embargo expired on 27-Jun-2016 at 11:00 ET)

Nature Structural & Molecular Biology

– Scripps Research Institute

IU Study Finds Testicular Cancer Survivors May Have Hearing Loss After Cisplatin Therapy

Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University.

(Embargo expired on 27-Jun-2016 at 16:00 ET)

Journal of Clinical Oncology, June 27, 2016; R01CA157823

– Indiana University

Fighting Prostate Cancer with Hi-Tech Might at NYU Lutheran

NYU Lutheran is determined to help stop prostate cancer in its tracks. And leading NYU Lutheran’s fight is Marc Bjurlin, DO, the hospital’s newly appointed director of urologic oncology and clinical assistant professor of urology at NYU School of Medicine.

 • Image(s) embedded •  (Embargo expired on 27-Jun-2016 at 06:00 ET)

– NYU Langone Medical Center

Many Women with Early Stage Breast Cancer Experience Functional Decline After Initiating Treatment

In a study of older women with newly diagnosed stage I to III breast cancer, approximately one in five lost the ability to complete some of the basic tasks necessary for independent living within one year of initiating treatment. Within 12 months, 34 of the 184 patients developed functional decline and seven died.

 • Image(s) embedded • 

– University Hospitals Case Medical Center

Normal Bacterial Colonies in Human Body Linked to Presence of Cancer of the Mouth and Throat

In a sample study, researchers at Johns Hopkins say they have found an association between the makeup of an individual’s microbiome and head and neck cancer, a finding that potentially advances the quest for faster and more accurate cancer diagnosis and therapy.

Oncotarget; U01CA84986, K01CA164092, CA121113, P50DE019032, RC2DE20957

– Johns Hopkins Medicine

Cross Talk Between Hormone Receptors Has Unexpected Effects

Although the estrogen receptor is considered dominant in breast cancer, the progesterone receptor assumes control when both receptors are present and exposed to estrogens and progestins. Then, the progesterone receptor drives estrogen receptor activity. Treating tumor-bearing mice with an estrogen antagonist and a progestin antagonist caused rapid tumor regression.

 • Image(s) embedded •  (Embargo expired on 24-Jun-2016 at 14:00 ET)

Science Advances, June 24, 2016

– University of Chicago Medical Center

In Mice, Daughters of Overweight Dads Have Altered Breast Tissue, Higher Cancer Risk

Obese male mice and normal weight female mice produce female pups that are overweight at birth through childhood, and have delayed development of their breast tissue as well as increased rates of breast cancer. The findings come from one of the first animal studies to examine the impact of paternal obesity on future generations’ cancer risk.

(Embargo expired on 24-Jun-2016 at 05:00 ET)

Scientific Reports

– Georgetown Lombardi Comprehensive Cancer Center

Primary Care Visits Result in More Colon Cancer Screening, Better Followups

People who visit their primary care physicians are more likely to get potentially life-saving colon cancer screenings and follow up on abnormal stool blood test results – even in health systems that heavily promote mail-in home stool blood tests that don’t require a doctor visit, a study involving UT Southwestern population health researchers shows.

 • Image(s) embedded • 

Journal of General Internal Medicine, June-2016

– UT Southwestern Medical Center

Modeling of the Universe with Einstein; Learning About the Future From the Distant Past; Particle Zoo in a Quantum Computer and More in the Physics News Source Sponsored by AIP

Click here to go directly to the Physics News Source Sponsored by AIP.

– Newswise

Mount Sinai’s Discovery of an Epigenetic Regulator of Tumorigenesis Suggests New Strategies Against Lethal Forms of Breast Cancer

Mount Sinai scientists have identified a previously unknown mechanism by which a protein called CBX8 promotes tumor growth in the most lethal forms of breast cancer. The study, published today in the journal Cell Reports, underscores the need for cancer researchers to pay more attention to “epigenetic” factors, meaning chemical and biological processes that control gene expression without changing the underlying DNA sequence of the cells that are running amok.

(Embargo expired on 23-Jun-2016 at 12:00 ET)

Cell Reports

– Mount Sinai Health System

Novel Gene-Hunting Method Implicates New Culprit in Pancreatic Cancer

Using an innovative approach to identify a cancer’s genetic vulnerabilities by more swiftly analyzing human tumors transplanted into mice, researchers have identified a new potential target for pancreatic cancer treatment, published online in Cell Reports.

 • Image(s) embedded • 

– University of Texas M. D. Anderson Cancer Center

Scientists Streamline Synthesis of Potential Cancer Drug

A team led by Rice University scientists has improved the production of a potent anti-tumor antibiotic known as uncialamycin.

 • Image(s) embedded • 

Journal of the American Chemical Society

– Rice University

Nanotechnology and Math Deliver Two-in-One Punch for Cancer Therapy Resistance

Math, biology and nanotechnology are becoming strange, yet effective bed-fellows in the fight against cancer treatment resistance. Researchers at the University of Waterloo and Harvard Medical School have engineered a revolutionary new approach to cancer treatment that pits a lethal combination of drugs together into a single nanoparticle.

 • Image(s) embedded • 

ACS Nano

– University of Waterloo

Researchers Discover How Faulty Genetic Instructions Drive a Deadly Blood Cancer in Adults

A study by UNC Lineberger Comprehensive Cancer Center researchers has revealed the genetic mechanism for how acute myeloid leukemia cells with a specific DNA mutation stay as undifferentiated cells.

 • Image(s) embedded • 

Cancer Cell, June-2016

– University of North Carolina Health Care System

New Cancer Immunotherapy Drugs Linked to Arthritis in Some Patients

Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers.

– Johns Hopkins Medicine

Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene

Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.

(Embargo expired on 22-Jun-2016 at 07:40 ET)

– Columbia University Medical Center

Contagious Cancers Are Spreading Among Several Species of Shellfish, Study Finds

New research suggests that direct transmission of cancer among marine animals may be much more common than once thought.

 • Video / Image(s) embedded •  (Embargo expired on 22-Jun-2016 at 13:00 ET)

– Columbia University Medical Center

High-Tech Scans Can Spare Lymphoma Patients Intensive Chemo

Hodgkin lymphoma patients can be spared the serious side effects of chemotherapy thanks to high-tech scans that can predict the outcome of treatment, according to a study published today in the New England Journal of Medicine*.

 • Image(s) embedded •  (Embargo expired on 22-Jun-2016 at 17:00 ET)

New England Journal of Medicine (2016). NEJMoa1510093_Johnson

– University of Southampton

Novel Combination Therapy Developed at VCU Massey Cancer Center Shows Strong Response in Patients with Advanced Solid Tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors.

 • Image(s) embedded • 

Oncotarget, March-2016; UL1TR000058; R01CA192613; R01DK52825; R01CA141703; R01CA150214 ; R01CA140416

– VCU Massey Cancer Center

Cancer, Violence Among Top Health Concerns for Chicago's South Siders

Residents on the South Side say cancer, violence prevention and sexually transmitted infections are among their top health concerns, according to the latest comprehensive assessment conducted by the University of Chicago Medicine. The 2016 Community Health Needs Assessment (CHNA), published online in mid-June, also identifies diabetes among adults, pediatric asthma and pediatric obesity as other critical health issues faced by South Siders. In addition to uncovering the community’s health needs, the report also includes a plan to advance outreach, prevention and education in those six health areas.

 • Image(s) embedded • 

– University of Chicago Medical Center


Support Children's Cancer Treatment at First Chicago Decathlon

Chicago area resident-athletes will have the opportunity to participate in a Decathlon at Lane Tech Stadium, Chicago, on August 6 and 7 to raise funds for pediatric cancer research at Rush. The Decathlon is a world-class athletic event for competitive amateur athletes from all professions testing speed, strength, endurance, agility, and coordination through a series of 10 challenges performed consecutively in one day.

– Rush University Medical Center

Valley and Mount Sinai Partner to Provide Comprehensive Cancer Care in Northern New Jersey

Valley Health System is pleased to partner with Mount Sinai Health System to offer state-of-the-art, comprehensive cancer care in northern New Jersey. This partnership will enable Valley to provide enhanced inpatient and outpatient cancer services by offering access to an expanded roster of clinical trials and Mount Sinai’s nationally renowned experts in the field of cancer care, and the development of new programs and services.

 • Image(s) embedded • 

– Valley Health System

Hitachi Chemical Co., Ltd. And MD Anderson Enter Into Strategic Alliance

Hitachi Chemical Co., Ltd. and The University of Texas MD Anderson Cancer Center have entered into a four-year strategic alliance funded by Hitachi to help develop and evaluate the company’s Micro Cavity Array (MCA) Circulating Tumor Cell (CTC) system for the isolation of CTC that can be subjected to downstream molecular analyses.

 • Image(s) embedded • 

– University of Texas M. D. Anderson Cancer Center

NYU’s Bluestone Center Awarded $1.2M from NIH to Investigate Gene Delivery for the Treatment of Oral Cancer Pain

Gene therapy is emerging as an exciting alternative to opioids for the treatment of cancer pain. The NYU researchers seek to alleviate oral cancer pain by reversing epigenetic changes, and using gene therapy, set the stage for a new class of medicines that selectively disrupt nociceptive signaling with fewer off-target effects.


– New York University

Upcoming Cancer ‘Moonshot’ Summit at Fred Hutch in Seattle

Fred Hutchinson Cancer Research Center will host one of hundreds of summits held around the country on June 29 in conjunction with the Vice President Joe Biden’s Cancer Moonshot Summit in Washington, DC. The goal of the Cancer Moonshot is to double the rate of progress in cancer prevention, diagnosis, treatment and care over the next five years to, ultimately, end cancer as we know it

– Fred Hutchinson Cancer Research Center

Updates from the American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting

Explore significant research developments and treatment advances relevant to oncology pharmacists presented at the ASPHO annual meeting at the Updates from the American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting webinar on July 14, 2016, from 12:00 – 1:00 pm CST.

– Hematology Oncology Pharmacy Association

Higher Education Events

Bidens’ Cancer Moonshot Summit to Bring National Cancer Community Together

Vice President Biden and Dr. Jill Biden will host a Cancer Moonshot Summit in Washington, D.C. at the White House. Cheryl Willman, MD, Director and CEO of The University of New Mexico Comprehensive Cancer Center, will attend. At the same time, the UNM Comprehensive Cancer Center will host a local Cancer Moonshot Summit.

– University of New Mexico Comprehensive Cancer Center

subscribe/unsubscribe :: edit my preferences
© 2016 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us